TheraXyte develops an extracellular vesicle (EV)-based drug delivery platform, TAXY®, that enables the mass production of modifiable EVs for targeted therapeutic applications. This technology addresses the challenge of delivering drugs effectively to previously inaccessible areas, such as the brain, while minimizing immunogenicity and enhancing treatment efficacy.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Effective drug delivery to specific tissues, particularly the brain, remains a significant challenge due to biological barriers and potential immunogenicity issues. Traditional drug delivery methods often fail to reach the intended target or cause adverse side effects, limiting treatment efficacy.
Solution
TheraXyte is developing TAXY®, an extracellular vesicle (EV)-based drug delivery platform designed for the mass production of modifiable EVs. This platform enables targeted delivery of therapeutic payloads to previously inaccessible areas, such as the brain, while minimizing immunogenicity. By leveraging the natural biological origins of EVs, TAXY® aims to enhance treatment efficacy and overcome the limitations of conventional drug delivery methods. The platform facilitates efficient cargo molecule loading and targeted release of therapeutics at the intended site of action.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing targeted therapies for diseases with unmet needs, particularly those requiring delivery across biological barriers.
Features
- TAXY® platform for mass production of modifiable extracellular vesicles (EVs)
- GMP-level manufacturing capabilities for clinical-grade EV production
- Enhanced drug encapsulation and targeted delivery to specific tissues and cells
- Ability to cross the blood-brain barrier for neurological applications
- Reduced immunogenicity due to the natural biological origin of EVs
- Flexible and modifiable EV composition for multifunctionality
- Comprehensive R&D system for EV production, cargo loading, and target delivery